| Trial ID: | L1648 |
| Source ID: | NCT01167309
|
| Associated Drug: |
Leo 27847
|
| Title: |
LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Secondary Hyperparathyroidism
|
| Interventions: |
DRUG: LEO 27847
|
| Outcome Measures: |
Primary: Safety and Tolerability, Adverse events, vital signs, ECG, laboratory evaluation, physical examination, 7 days after last dosing | Secondary: Pharmacokinetics and Pharmacodynamics, LEO 27847, PTH, calcium, Vitamin D and phosphate in blood. LEO 27847 in urine, 7 days after last dosing
|
| Sponsor/Collaborators: |
Sponsor: LEO Pharma
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
72
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER
|
| Start Date: |
2010-06
|
| Completion Date: |
2011-12
|
| Results First Posted: |
|
| Last Update Posted: |
2025-02-24
|
| Locations: |
CRS Clinical Research Services Kiel GmbH, Kiel, 24105, Germany|Centralny Szpital Kliniczny MON, Warszawa, 04-141, Poland
|
| URL: |
https://clinicaltrials.gov/show/NCT01167309
|
